BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thelen M, Wennhold K, Lehmann J, Garcia-Marquez M, Klein S, Kochen E, Lohneis P, Lechner A, Wagener-Ryczek S, Plum PS, Velazquez Camacho O, Pfister D, Dörr F, Heldwein M, Hekmat K, Beutner D, Klussmann JP, Thangarajah F, Ratiu D, Malter W, Merkelbach-Bruse S, Bruns CJ, Quaas A, von Bergwelt-Baildon M, Schlößer HA. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. NPJ Precis Oncol 2021;5:52. [PMID: 34135436 DOI: 10.1038/s41698-021-00196-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Miebach L, Berner J, Bekeschus S. In ovo model in cancer research and tumor immunology. Front Immunol 2022;13:1006064. [DOI: 10.3389/fimmu.2022.1006064] [Reference Citation Analysis]
2 Choi Y, Son W, Han Y, Chae J, Yang C, Choi J. Glycan targeting nanoparticle for photodynamic immunotherapy of melanoma. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.009] [Reference Citation Analysis]
3 Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-illescas D, Pardo N, Navarro A, Martinez-marti A, Cedres S, Carbonell C, Frigola J, Amat R, Felip E. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med 2022;9:875974. [DOI: 10.3389/fmed.2022.875974] [Reference Citation Analysis]
4 Gockel LM, Nekipelov K, Ferro V, Bendas G, Schlesinger M. Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin. Cancer Immunol Immunother 2022. [PMID: 35285006 DOI: 10.1007/s00262-022-03186-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen L, Kong X, Huang S, Su Z, Zhu M, Fang Y, Zhang L, Li X, Wang J. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Front Immunol 2022;13:831848. [DOI: 10.3389/fimmu.2022.831848] [Reference Citation Analysis]
6 Saini KS, Svane IM, Juan M, Barlesi F, André F. Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges. Ann Oncol 2021:S0923-7534(21)04518-X. [PMID: 34655734 DOI: 10.1016/j.annonc.2021.09.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sharma S, George P, Waddell N. Precision diagnostics: Integration of tissue pathology and genomics in cancer. Pathology 2021:S0031-3025(21)00471-2. [PMID: 34635323 DOI: 10.1016/j.pathol.2021.08.003] [Reference Citation Analysis]
8 Garcia-Marquez MA, Thelen M, Reinke S, Keller D, Wennhold K, Lehmann J, Veldman J, Borchmann S, Rosenwald A, Sasse S, Diepstra A, Borchmann P, Engert A, Klapper W, von Bergwelt-Baildon M, Bröckelmann PJ, Schlößer HA. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. Leukemia 2021. [PMID: 34584203 DOI: 10.1038/s41375-021-01421-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. ACS Nano 2021. [PMID: 34339170 DOI: 10.1021/acsnano.1c02103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]